PHARMA MAR, S.A. – Consensus Indicates Potential -96.9% Downside

DirectorsTalk Interviews

PHARMA MAR, S.A. found using the Ticker (PHM.MC) now have 7 analysts commenting on the stock. The overall consensus points to a recommendation of ‘buy’. The target price ranges between €5.60 and €1.75 and has a mean target at €3.52. With the stocks previous close at €113.50 this now indicates there is a potential downside of -96.9%. The 50 day MA is €84.53 and the 200 day moving average is €95.30. The market cap for the company is €2b. Company Website: http://www.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Twitter
    LinkedIn
    Facebook
    Email
    Reddit

      AIM All Share Index